Eli Lilly has filed a new migraine drug, lasmiditan, with the US regulator, the first drug in its class to be reviewed as a treatment for the condition.
Ionis affiliate Akcea Pharma has new data for its antisense drug for elevated lipoprotein levels in patients with cardiovascular disease that it hopes will entice Novartis into a licensing deal.
Two years ago, Novartis launched a big trials programme for its heart failure drug Entresto in the hope of revving up disappointing initial sales, and one of those trials has just delivered positiv
Novartis says it thinks its one-off gene therapy for spinal muscular atrophy (SMA) could deliver value for money even if its price was set upwards of $4 million – which would set a record f
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
